DUBLIN--(BUSINESS WIRE)--The "Biologics Outsourcing Global Market" report has been added to ResearchAndMarkets.com's offering.
The biologics outsourcing global market is expected to grow at double digit CAGR to reach $87.6 billion by 2027.
Biologics are therapeutic entities composed of sugars, proteins, or nucleic acids made from natural sources such as human, animal or micro organisms. Biologics can also include live attenuated microorganisms (vaccines), allergenic extracts (allergy shots), human cells and tissues (transplantation), cell therapies and gene therapies. Like small molecule drugs, these drugs are intended for treatment of diseases and medical conditions.
However, Biologics bring into picture higher range of specificity in treating a disease condition as the biologic entities like monoclonal antibodies and recombinant proteins target specific areas in the molecular mechanism of disease action.
Although biologics are much costlier than small molecule drugs, these classes of drugs prove to be highly beneficial for the patient and also bring about 40% higher profits to the manufacturers when compared to small molecule drug treatments. Due to the increasing demand for biologics drugs and increased regulatory approvals for these drugs, there is huge demand for biologics manufacture and testing at various levels of clinical studies as well as commercial supply.
The Large Biopharma companies are coming up with strategies to cut down on their operational costs and concentrate more on their core competencies by outsourcing this piece of work to contract research organizations (CROs), contract development and manufacturing organizations (CDMOs) and contract manufacturing organizations (CMOs).
These organizations bridge the gap between demand and supply and ensure the drug discovery process gets much faster and convenient thus bringing life saving drugs to the market to reach the needy patients.
In 2017, 7 out of 10 blockbuster drugs were biologics outnumbering small molecule drugs. Some of the top selling biologics in 2017 includes Humira ($18.4 billion), Rituxan ($9.2 billion), Enbrel ($7.9 billion), and Herceptin ($7.4 billion). The growth of biologics market indirectly indicates the huge demand for services spanning all stages of biologics development starting preclinical stage to commercial manufacturing.
Key Topics Covered:
1 Biologics Outsourcing Global Market
2 Market Analysis
Scope For Biosimilars
Lack Of Facilities For Discovery And Manufacturing Of Biologics
3 Biologics Outsourcing Global Market, Market Analysis
4 Biologics Outsourcing Global Market - Animal Model Services
5 Biologics Outsourcing Global Market - Biomanufacturing
6 Biologics Outsourcing Global Market - Cell Line Development
7 Company Profiles
- Abzena Plc
- Adimab Llc.
- Albany Molecular Research, Inc
- Beijing Vital Star Biotechnology Co. Ltd.
- Boehringer Ingelheim
- Catalent Inc.
- Charles River Laboratories
- Crown Biosciences (JSR)
- Genoway
- Genscript Biotech Corporation
- GL Biochem
- Horizon Discovery Group, Plc
- Jackson Laboratory
- Samsung Biologics
- JHL Biotech Inc.
- Joinn Laboratories Co. Ltd
- Lonza Group
- Merck KGaA
- Patheon N.V. (Thermofisher Scientific)
- Pharmalegacy Laboratories
- Pharmaron
- Prosci Inc.
- Proteogenix
- Psychogenics, Inc
- JSR Life Sciences (Selexis SA)
- Shanghai Medicilon
- Shangpharma Corporation /Shanghai Chempartner
- Sino Biological
- Sundia Meditech Co., Ltd.
- Syngene International
- Taconic Biosciences
- Viva Biotech Ltd.
- Wuxi Biologics (Wuxi Apptec)
For more information about this report visit https://www.researchandmarkets.com/research/84fwrd/global_87_6?w=4
